Recognizing a parallel in the hurdles and obstacles to commercialization between the personalized medicine space and the microbiome field, the Arrowhead Translational Microbiome Conference was launched in 2014 with the goal of bringing together the leading microbiome companies and key thinkers in the field to begin discussing these hurdles and how they could best be addressed.

Following a successful first conference, a small group of innovative and forward thinking companies came together in the summer of 2015 to submit a response to a Request for Information on the microbiome put out by the Office of Science and Technology Policy in the White House. That response can be read [here].

Through the process of drafting that response, these companies recognized the need for a coordinated effort to promote greater public understanding of the role of the microbiome in human health and wellness and to provide this growing field with the greater power to engage the regulatory agencies that comes from a cohesive voice.

The following companies, through their corporate representatives, have provided initial funding to support the launch of TMBC and have provided generously of their time and expertise in guiding its development:

AO Biome
Larry Weiss, MD, Chief Medical Officer

 Abbott Nutrition
JoMay Chow, Ph.D., Senior Research Scientist

Manoj Dadlani, CEO

Joseph F. Petrosino, Ph.D., Founder and Chief Scientific Officer

Mayo Clinic
Purna Kashyap, MBBS, Assistant Professor at Mayo Clinic
Kelly Krajnik, Business Development Manager

Second Genome
Mohan S. Iyer, Chief Business Officer

Whole Biome
Colleen Cutcliffe, Ph.D., CEO and Co-Founder